

Gianluca Tomasello

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12029077/publications.pdf>

Version: 2024-02-01

68
papers

4,049
citations

279487

23
h-index

123241

61
g-index

68
all docs

68
docs citations

68
times ranked

5556
citing authors

#	ARTICLE	IF	CITATIONS
1	Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer. <i>New England Journal of Medicine</i> , 2014, 371, 1609-1618.	13.9	845
2	FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. <i>Lancet Oncology</i> , The, 2015, 16, 1306-1315.	5.1	835
3	Prognostic Survival Associated With Left-Sided vs Right-Sided Colon Cancer. <i>JAMA Oncology</i> , 2017, 3, 211.	3.4	544
4	Association of Obesity With Survival Outcomes in Patients With Cancer. <i>JAMA Network Open</i> , 2021, 4, e213520.	2.8	197
5	Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. <i>Lancet Oncology</i> , The, 2020, 21, 497-507.	5.1	196
6	FOLFOXIRI Plus Bevacizumab as Conversion Therapy for Patients With Initially Unresectable Metastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2017, 3, e170278.	3.4	152
7	The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials. <i>British Journal of Cancer</i> , 2020, 123, 403-409.	2.9	93
8	Comparative Effectiveness of Gemcitabine plus Nab-Paclitaxel and FOLFIRINOX in the First-Line Setting of Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2019, 11, 484.	1.7	79
9	Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With <i>RAS</i> Wild-Type Metastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2019, 5, 1268.	3.4	70
10	Negative Hyperselection of Patients With <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy. <i>Journal of Clinical Oncology</i> , 2019, 37, 3099-3110.	0.8	65
11	Adjuvant Low-Dose Interleukin-2 (IL-2) Plus Interferon- γ (IFN- γ) in Operable Renal Cell Carcinoma (RCC). <i>Journal of Immunotherapy</i> , 2014, 37, 440-447.	1.2	61
12	Prognostic Role of Primary Tumor Location in Non-Metastatic Gastric Cancer: A Systematic Review and Meta-Analysis of 50 Studies. <i>Annals of Surgical Oncology</i> , 2017, 24, 2655-2668.	0.7	55
13	Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest. <i>European Journal of Cancer</i> , 2017, 73, 74-84.	1.3	54
14	A validated prognostic classifier for BRAF-mutated metastatic colorectal cancer: the "BRAF BeCool"™ study. <i>European Journal of Cancer</i> , 2019, 118, 121-130.	1.3	51
15	Adjuvant chemotherapy for resected biliary tract cancers: a systematic review and meta-analysis. <i>Hpb</i> , 2017, 19, 741-748.	0.1	48
16	Outcome of head compared to body and tail pancreatic cancer: a systematic review and meta-analysis of 93 studies. <i>Journal of Gastrointestinal Oncology</i> , 2019, 10, 259-269.	0.6	44
17	Neoadjuvant chemoradiotherapy or chemotherapy for gastroesophageal junction adenocarcinoma: A systematic review and meta-analysis. <i>Gastric Cancer</i> , 2019, 22, 245-254.	2.7	42
18	Biliary tract cancer: current challenges and future prospects. <i>Cancer Management and Research</i> , 2019, Volume 11, 379-388.	0.9	41

#	ARTICLE	IF	CITATIONS
19	Ramucirumab as Second-Line Therapy in Metastatic Gastric Cancer: Real-World Data from the RAMoss Study. <i>Targeted Oncology</i> , 2018, 13, 227-234.	1.7	33
20	Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world. <i>Gastric Cancer</i> , 2017, 20, 825-833.	2.7	32
21	TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group. <i>BMC Cancer</i> , 2017, 17, 408.	1.1	28
22	Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy. <i>Oncologist</i> , 2017, 22, 1463-1469.	1.9	27
23	Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic Implications. <i>Journal of the National Cancer Institute</i> , 2022, 114, 271-279.	3.0	27
24	Surrogate end-points for overall survival in 22 neoadjuvant trials of gastro-oesophageal cancers. <i>European Journal of Cancer</i> , 2017, 76, 8-16.	1.3	25
25	<i>DPYD</i> and <i>UGT1A1</i> genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer. <i>Oncotarget</i> , 2018, 9, 7859-7866.	0.8	25
26	Phase III, randomised, multicentre trial of maintenance immunotherapy with low-dose interleukin-2 and interferon- γ for metastatic renal cell cancer. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 553-561.	2.0	22
27	Right Versus Left Colon Cancer: Resectable and Metastatic Disease. <i>Current Treatment Options in Oncology</i> , 2018, 19, 31.	1.3	21
28	Impact of BMI on Survival Outcomes of Immunotherapy in Solid Tumors: A Systematic Review. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2628.	1.8	21
29	A Review of Clinical Practice Guidelines and Treatment Recommendations for Cancer Care in the COVID-19 Pandemic. <i>Cancers</i> , 2020, 12, 2452.	1.7	20
30	Oligometastatic colorectal cancer: prognosis, role of locoregional treatments and impact of first-line chemotherapy—a pooled analysis of TRIBE and TRIBE2 studies by Gruppo Oncologico del Nord Ovest. <i>European Journal of Cancer</i> , 2020, 139, 81-89.	1.3	17
31	Lipegfilgrastim for the prophylaxis and treatment of chemotherapy-induced neutropenia. <i>Expert Review of Clinical Pharmacology</i> , 2015, 8, 15-24.	1.3	16
32	The Added Value of Baseline Circulating Tumor DNA Profiling in Patients with Molecularly Hyperselected, Left-sided Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 2505-2514.	3.2	14
33	Immunotherapy options in metastatic renal cell cancer: where we are and where we are going. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 1459-1472.	1.1	13
34	Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study. <i>European Journal of Cancer</i> , 2021, 155, 73-84.	1.3	13
35	Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial. <i>BMC Cancer</i> , 2019, 19, 283.	1.1	12
36	Impact of early tumor shrinkage and depth of response on the outcomes of panitumumab-based maintenance in patients with RAS wild-type metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2021, 144, 31-40.	1.3	12

#	ARTICLE	IF	CITATIONS
37	Estimating Survival Probabilities of Advanced Gastric Cancer Patients in the Second-Line Setting: The Gastric Life Nomogram. <i>Oncology</i> , 2018, 95, 344-352.	0.9	11
38	Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with panitumumab-based first-line treatment strategy: A pre-specified secondary analysis of the Valentino study. <i>European Journal of Cancer</i> , 2020, 135, 230-239.	1.3	11
39	Lactobacillus Kefiri LKF01 (Kefibios®) for Prevention of Diarrhoea in Cancer Patients Treated with Chemotherapy: A Prospective Study. <i>Nutrients</i> , 2021, 13, 385.	1.7	10
40	Preferred neoadjuvant therapy for gastric and gastroesophageal junction adenocarcinoma: a systematic review and network meta-analysis. <i>Gastric Cancer</i> , 2022, 25, 982-987.	2.7	10
41	Efficacy and tolerability of chemotherapy with modified dose-dense TCF regimen (TCF-dd) in locally advanced or metastatic gastric cancer: final results of a phase II trial. <i>Gastric Cancer</i> , 2014, 17, 711-717.	2.7	9
42	Strong Notch activation hinders bevacizumab efficacy in advanced colorectal cancer. <i>Future Oncology</i> , 2015, 11, 3167-3174.	1.1	9
43	New developments in the treatment of chemotherapy-induced neutropenia: focus on balugrastim. <i>Therapeutics and Clinical Risk Management</i> , 2016, Volume 12, 1009-1015.	0.9	9
44	Modified schedules of DCF chemotherapy for advanced gastric cancer. <i>Anti-Cancer Drugs</i> , 2017, 28, 133-141.	0.7	9
45	CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies. <i>British Journal of Cancer</i> , 2021, 125, 839-845.	2.9	9
46	A Pilot Phase ii Study of Chemotherapy with Oxaliplatin, Folinic acid, 5-Fluorouracil and Irinotecan in Metastatic Gastric Cancer. <i>Tumori</i> , 2007, 93, 244-247.	0.6	8
47	Dose-dense Chemotherapy in Metastatic Gastric Cancer with a Modified Docetaxel-Cisplatin-5-Fluorouracil Regimen. <i>Tumori</i> , 2010, 96, 48-53.	0.6	8
48	High levels of Notch intracellular cleaved domain are associated with stemness and reduced bevacizumab efficacy in patients with advanced colon cancer. <i>Oncology Reports</i> , 2019, 42, 2750-2758.	1.2	7
49	Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO. <i>British Journal of Cancer</i> , 2021, 124, 183-190.	2.9	7
50	Dose-dense chemotherapy in metastatic gastric cancer with a modified docetaxel-cisplatin-5-fluorouracil regimen. <i>Tumori</i> , 2010, 96, 48-53.	0.6	7
51	First-line dose-dense chemotherapy with docetaxel, cisplatin, folinic acid and 5-fluorouracil (DCF) plus panitumumab in patients with locally advanced or metastatic cancer of the stomach or gastroesophageal junction: final results and biomarker analysis from an Italian oncology group for clinical research (GOIRC) phase II study. <i>Oncotarget</i> , 2017, 8, 111795-111806.	0.8	6
52	Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study. <i>Journal of Geriatric Oncology</i> , 2019, 10, 591-597.	0.5	6
53	The Emergence of Immune-checkpoint Inhibitors in Colorectal Cancer Therapy. <i>Current Drug Targets</i> , 2021, 22, 1021-1033.	1.0	6
54	Total neoadjuvant therapy for initially inoperable pancreatic cancer: A systematic review of phase 2-3 studies. <i>Radiotherapy and Oncology</i> , 2021, 164, 13-19.	0.3	6

#	ARTICLE	IF	CITATIONS
55	Survival benefit with adjuvant chemotherapy in stage III microsatellite-high/deficient mismatch repair colon cancer: a systematic review and meta-analysis. <i>Scientific Reports</i> , 2022, 12, 1055.	1.6	6
56	Glycolytic competence in gastric adenocarcinomas negatively impacts survival outcomes of patients treated with salvage paclitaxel-ramucirumab. <i>Gastric Cancer</i> , 2020, 23, 1064-1074.	2.7	5
57	Exploring clinical and gene expression markers of benefit from FOLFOXIRI/bevacizumab in patients with BRAF-mutated metastatic colorectal cancer: Subgroup analyses of the TRIBE2 study. <i>European Journal of Cancer</i> , 2021, 153, 16-26.	1.3	5
58	Post-induction Strategies in Metastatic Colorectal Cancer Patients Treated With First-Line Anti-EGFR-Based Treatment: A Systematic Review and Meta-Analysis. <i>Clinical Colorectal Cancer</i> , 2022, 21, e162-e170.	1.0	5
59	A pilot phase II study of chemotherapy with oxaliplatin, folinic acid, 5-fluorouracil and irinotecan in metastatic gastric cancer. <i>Tumori</i> , 2007, 93, 244-7.	0.6	5
60	Systemic doxycycline for pre-emptive treatment of anti-EGFR-related skin toxicity in patients with metastatic colorectal cancer receiving first-line panitumumab-based therapy: a post hoc analysis of the Valentino study. <i>Supportive Care in Cancer</i> , 2021, 29, 3971-3980.	1.0	4
61	Nivolumab plus ipilimumab for the first-line treatment of metastatic NSCLC. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 705-713.	1.1	4
62	Neoadjuvant Treatment for Pancreatic Adenocarcinoma: A False Promise or an Opportunity to Improve Outcome?. <i>Cancers</i> , 2021, 13, 4396.	1.7	4
63	The Appropriateness of Invasive Ventilation in COVID-19 Positive Cancer Patients: Proposal of a New Prognostic Score. <i>Viruses</i> , 2021, 13, 508.	1.5	3
64	Predictors of Lymph Node Metastasis in T1 Colorectal Cancer in Young Patients: Results from a National Cancer Registry. <i>Journal of Clinical Medicine</i> , 2021, 10, 5511.	1.0	3
65	Prognostic and Predictive Role of Body Mass Index (BMI) in Metastatic Colorectal Cancer (mCRC): A Pooled Analysis of Tribe and Tribe-2 Studies by GONO. <i>Clinical Colorectal Cancer</i> , 2022, , .	1.0	3
66	Safety and Efficacy of Dose-dense Chemotherapy with TCF Regimen in Elderly Patients with Locally Advanced or Metastatic Gastric Cancer. <i>Tumori</i> , 2017, 103, 93-100.	0.6	2
67	Sequential chemotherapy with dose-dense docetaxel, cisplatin, folinic acid and 5-fluorouracil (TCF-dd) followed by combination of oxaliplatin, folinic acid, 5-fluorouracil and irinotecan (COFFI) in metastatic gastric cancer: results of a phase II trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 41-48.	1.1	1
68	Advances in the pharmacological management of neutropenia in solid tumors: the advent of biosimilars. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 857-865.	0.9	1